Announced
Financials
Tags
Pending
Majority
Single Bidder
Merger
biotechnology platform
biopharma
United States
Friendly
epinephrine product
tissue targeted therapeutics
Biotechnology
Acquisition
Private
Domestic
Synopsis
ARS Pharmaceuticals, a pharmaceutical company, specializing in anti-allergy drugs, agreed to merge with Silverback Therapeutics, a biopharmaceutical company, in a $144m deal. “We are extremely pleased to announce this proposed merger with Silverback, which we believe enables ARS to maximize the paradigm-changing opportunity of neffy. neffy is on the cusp of achieving what has not been possible before – the ability to deliver epinephrine with comparable pharmacokinetics to an intramuscular injection, but with a simple to administer nasal spray. We have completed a comprehensive registration program with neffy and based on a favorable pre-NDA meeting with the US Food and Drug Administration, we are preparing to submit our New Drug Application in the third quarter of 2022. This merger positions ARS and our experienced team to execute on the potential launch of neffy in 2023 by providing the requisite capital needed for launch,” Richard Lowenthal, ARS Co-Founder and CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.